Physician profile
Peter David Dryer
NPI 1639380934
$14,938.84
in general payments reported to CMS, 2019-2025
40 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,549 · 2020: $1,668 · 2021: $3,215 · 2022: $1,705 · 2023: $2,257 · 2024: $1,293 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,551.85 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,081.49 | 2019-2020 | |
| Abbvie INC. | $3,780.01 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,331.03 | 2019-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $1,289.71 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $637.79 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $364.76 | 2019-2025 | Simponi Aria, Simponi, Stelara |
| Medtronic, INC. | $302.38 | 2024-2025 | Interstim, Gi Genius |
| Madrigal Pharmaceuticals | $265.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $261.66 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $251.39 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $236.97 | 2021-2022 | |
| Celgene Corporation | $207.53 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $198.18 | 2019-2024 | Rebyota |
| Pfizer INC. | $189.90 | 2019-2025 | |
| Qol Medical, LLC | $184.50 | 2022-2025 | Sucraid, Sucraid |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Dryer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.